Saturday 17 October 2026
Export ZOMDF’s income statement to Excel — free account
Zomedica Corp.
ZOMDF Healthcare Medical Devices
Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.6%, EPS grew 49.3% and free cash flow grew 40.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.08
0.00
0.00%
Follow ZOMDF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.66 | 3.43 | 3.06 | 2.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(38.41) | (22.37) | (109.00) | (16.82) | |
P/B ratio |
0.91 | 1.06 | 0.85 | 0.66 | |
Price to Tangible BV |
1.40 | 1.61 | 1.28 | 0.99 | |
EV/Sales |
1.47 | 2.06 | 1.41 | 0.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.07) | (4.34) | (2.56) | (1.21) | |
EV/FCF |
(3.62) | (4.08) | (2.43) | (1.07) | |
Quick Ratio |
5.57 | 6.11 | 6.00 | 6.73 | |
Current Ratio |
6.43 | 7.01 | 6.78 | 7.67 | |
Net Debt/EBITDA |
19.06 | 15.26 | 15.88 | 10.96 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.29 | 0.26 | 0.19 | 0.17 | |
Operating CF/Net income |
0.68 | 1.16 | 0.20 | 0.76 | |
Capex/Depreciation |
(0.46) | (0.29) | (0.10) | (0.08) | |
Research and Development Expense of Revenue |
11.25% | 13.12% | 15.69% | 22.04% | |
Selling, General and Administrative Expense of Revenue |
95.19% | 104.90% | 102.10% | 126.72% | |
Intangible Assets out of Total Assets |
0.32 | 0.31 | 0.31 | 0.31 | |
Share Based Compensation of Revenue |
0.73% | 7.31% | 6.94% | 10.71% | |
Graham Net Nets |
0.48 | 0.42 | 0.53 | 0.68 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.20%) | (19.08%) | (88.30%) | (113.75%) | |
Free Cash Flow Yield |
(15.33%) | (14.73%) | (18.98%) | (30.76%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Cash per Share |
0.05 | 0.05 | 0.05 | 0.05 | |
Shareholders Equity per Share |
0.11 | 0.11 | 0.12 | 0.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.11 | 0.11 | 0.12 | 0.12 | |
Free Cash Flow |
(3.37) | (5.77) | (1.09) | (4.80) | |
Working Capital |
48.89 | 51.47 | 54.59 | 56.26 | |
Capital Expenditures |
(0.82) | (0.51) | (0.19) | (0.14) | |
Net Current Asset Value |
47.03 | 49.44 | 52.40 | 53.48 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | 0.06 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.47 | 3.46 | 3.26 | 3.01 | |
Average Payables |
1.82 | 2.25 | 1.82 | 2.01 | |
Average Inventory |
5.86 | 5.62 | 5.30 | 5.48 | |
Average Assets |
127.31 | 132.26 | 167.20 | 172.51 | |
Average Common Equity |
116.32 | 121.69 | 155.53 | 161.27 |
Columns are period end dates